212 related articles for article (PubMed ID: 18055323)
21. BRAF(K601E) mutation in a patient with a follicular thyroid carcinoma.
Pennelli G; Vianello F; Barollo S; Pezzani R; Merante Boschin I; Pelizzo MR; Mantero F; Rugge M; Mian C
Thyroid; 2011 Dec; 21(12):1393-6. PubMed ID: 22136270
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetic study comparing follicular variant versus classic papillary thyroid carcinomas: association of N-ras mutation in codon 61 with follicular variant.
Di Cristofaro J; Marcy M; Vasko V; Sebag F; Fakhry N; Wynford-Thomas D; De Micco C
Hum Pathol; 2006 Jul; 37(7):824-30. PubMed ID: 16784981
[TBL] [Abstract][Full Text] [Related]
23. Concomitant BRAF(V600E) mutation and RET/PTC rearrangement is a frequent occurrence in papillary thyroid carcinoma.
Guerra A; Zeppa P; Bifulco M; Vitale M
Thyroid; 2014 Feb; 24(2):254-9. PubMed ID: 23806056
[TBL] [Abstract][Full Text] [Related]
24. New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy.
Riesco-Eizaguirre G; Santisteban P
Endocr Relat Cancer; 2007 Dec; 14(4):957-77. PubMed ID: 18045949
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Abubaker J; Jehan Z; Bavi P; Sultana M; Al-Harbi S; Ibrahim M; Al-Nuaim A; Ahmed M; Amin T; Al-Fehaily M; Al-Sanea O; Al-Dayel F; Uddin S; Al-Kuraya KS
J Clin Endocrinol Metab; 2008 Feb; 93(2):611-8. PubMed ID: 18000091
[TBL] [Abstract][Full Text] [Related]
26. Pathology and genetics of thyroid carcinoma.
DeLellis RA
J Surg Oncol; 2006 Dec; 94(8):662-9. PubMed ID: 17131411
[TBL] [Abstract][Full Text] [Related]
27. Genetics of papillary thyroid cancer initiation: implications for therapy.
Fagin JA
Trans Am Clin Climatol Assoc; 2005; 116():259-69; discussion 269-71. PubMed ID: 16555619
[TBL] [Abstract][Full Text] [Related]
28. [Advances in studies of the genes related to thyroid carcinoma].
Zhi JT; Zheng XQ; Gao M
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Dec; 51(12):951-955. PubMed ID: 27978891
[TBL] [Abstract][Full Text] [Related]
29. Simultaneous occurrence of PAX8-PPARg and RET-PTC3 rearrangements in a follicular variant of papillary thyroid carcinoma.
Caria P; Dettori T; Frau DV; Di Oto E; Morandi L; Parmeggiani A; Tallini G; Vanni R
Am J Surg Pathol; 2012 Sep; 36(9):1415-20. PubMed ID: 22895275
[TBL] [Abstract][Full Text] [Related]
30. [Intracellular signaling mechanisms in thyroid cancer].
Mondragón-Terán P; López-Hernández LB; Gutiérrez-Salinas J; Suárez-Cuenca JA; Luna-Ceballos RI; Erazo Valle-Solís A
Cir Cir; 2016; 84(5):434-43. PubMed ID: 27423883
[TBL] [Abstract][Full Text] [Related]
31. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.
Xu X; Quiros RM; Gattuso P; Ain KB; Prinz RA
Cancer Res; 2003 Aug; 63(15):4561-7. PubMed ID: 12907632
[TBL] [Abstract][Full Text] [Related]
32. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
33. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
34. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
35. BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications.
Tang KT; Lee CH
J Chin Med Assoc; 2010 Mar; 73(3):113-28. PubMed ID: 20230995
[TBL] [Abstract][Full Text] [Related]
36. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma.
Kure S; Wada R; Naito Z
Med Mol Morphol; 2019 Dec; 52(4):181-186. PubMed ID: 30788603
[TBL] [Abstract][Full Text] [Related]
37. Geographical mapping of a multifocal thyroid tumour using genetic alteration analysis & miRNA profiling.
Aherne ST; Smyth PC; Flavin RJ; Russell SM; Denning KM; Li JH; Guenther SM; O'Leary JJ; Sheils OM
Mol Cancer; 2008 Dec; 7():89. PubMed ID: 19055826
[TBL] [Abstract][Full Text] [Related]
38. Characterization of Activating Mutations of the
Borrelli N; Panebianco F; Condello V; Barletta JA; Kaya C; Yip L; Nikiforova MN; Nikiforov YE
Thyroid; 2019 Sep; 29(9):1279-1285. PubMed ID: 31407636
[No Abstract] [Full Text] [Related]
39. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.
Puxeddu E; Moretti S; Elisei R; Romei C; Pascucci R; Martinelli M; Marino C; Avenia N; Rossi ED; Fadda G; Cavaliere A; Ribacchi R; Falorni A; Pontecorvi A; Pacini F; Pinchera A; Santeusanio F
J Clin Endocrinol Metab; 2004 May; 89(5):2414-20. PubMed ID: 15126572
[TBL] [Abstract][Full Text] [Related]
40. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors.
Hou P; Ji M; Xing M
Cancer; 2008 Nov; 113(9):2440-7. PubMed ID: 18831514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]